Arina Ilina

Dr. Arina Ilina


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Anton KiselevAnton Kiselev
Anton Kiselev
MMMarianna Maretina
Marianna Maretina
SSSofia Shtykalova
Sofia Shtykalova
HHHaya Al Hilal
Haya Al Hilal
NMNatalia Maslyanyuk
Natalia Maslyanyuk
Andrey Sergeevich GlotovAndrey Sergeevich Glotov
Andrey Sergeevich Glotov
Spinal muscular atrophy 5q (SMA) is one of the most common neuromuscular inherited diseases and is the most common genetic cause of infant mortality. SMA is associated with homozygous deletion of exon 7 in the SMN1 gene. Recently developed drugs can improve the motor functions of infants with SMA when they are treated in the pre-symptomatic stage. With aim of providing an early diagnosis, newborn screening (NBS) for SMA using a real-time PCR assay with dried blood spots (DBS) was performed from January 2022 through November 2022 in Saint Petersburg, which is a representative Russian megapolis. Here, 36,140 newborns were screened by the GenomeX real-time PCR-based screening test, and three genotypes were identified: homozygous deletion carriers (4 newborns), heterozygous carriers (772 newborns), and wild-type individuals (35,364 newborns). The disease status of all four newborns that screened positive for the homozygous SMN1 deletion was confirmed by alternate methods. Two of the newborns had two copies of SMN2, and two of the newborns had three copies. We determined the incidence of spinal muscular atrophy in Saint Petersburg to be 1 in 9035 and the SMA carrier frequency to be 1 in 47. In conclusion, providing timely information regarding SMN1, confirmation of disease status, and SMN2 copy number as part of the SMA newborn-screening algorithm can significantly improve clinical follow-up, testing of family members, and treatment of patients with SMA.

16 November 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
MMMarianna Maretina
Marianna Maretina
AIArina Ilina
Arina Ilina
AEAnna Egorova
Anna Egorova
Andrey Sergeevich GlotovAndrey Sergeevich Glotov
Andrey Sergeevich Glotov
Anton KiselevAnton Kiselev
Anton Kiselev
Spinal muscular atrophy (SMA) is a devastating neurodegenerative disease caused by mutations in the SMN1 gene. Existing therapies demonstrate positive results on SMA patients but still might be ameliorated in efficacy and price. In the presented study we designed antisense oligonucleotides (AONs), targeting intronic splicing silencer sites, some were modified with 2′-O-methyl, others with LNA. The AONs have been extensively tested in different concentrations, both individually and combined, in order to effectively target the ISS-N1 and A+100G splicing silencer regions in intron 7 of the SMN2 gene. By treating SMA-cultured fibroblasts with certain AONs, we discovered a remarkable increase in the levels of full-length SMN transcripts and the number of nuclear gems. This increase was observed to be dose-dependent and reached levels comparable to those found in healthy cells. When added to cells together, most of the tested molecules showed a remarkable synergistic effect in correcting splicing. Through our research, we have discovered that the impact of oligonucleotides is greatly influenced by their length, sequence, and pattern of modification.

26 May 2022 in Annals of the Russian academy of medical sciences
Verified
Journal Article
Closed access
PDF file
MMMarianna A. Maretina
Marianna A. Maretina
Anton KiselevAnton Kiselev
Anton Kiselev
AIArina Ilina
Arina Ilina
AEAnna A. Egorova
Anna A. Egorova
Andrey Sergeevich GlotovAndrey Sergeevich Glotov
Andrey Sergeevich Glotov
IKIgor Yu. Kogan
Igor Yu. Kogan
Spinal muscular atrophy is one of the most severe hereditary neuromuscular diseases and one of the main causes of infant mortality caused by hereditary diseases. Being a monogenic disease, SMA is characterized by a wide range of phenotypes, which are based on the influence of genetic modifiers of the disease. These modifiers determine the development of a more severe or milder form of the disease and can act as potential targets of disease therapy. To date, there are three certified drugs for the treatment of SMA, the action of two of them is directed at the transcript of the main modifier of the disease the SMN2 gene. With the advent of effective therapy, the issue of screening newborns for the purpose of early detection of patients and the beginning of treatment of SMA at the presymptomatic phase to achieve maximum effectiveness of drugs becomes relevant. In addition to neonatal screening, population screening plays an important role, which may result in a decrease in the frequency of births of children with SMA.

14 August 2025 in Scientia Pharmaceutica
Verified
Journal Article
Open access
PDF file
MMMarianna Maretina
Marianna Maretina
AEAnna Egorova
Anna Egorova
AIArina Ilina
Arina Ilina
NKNadezhda Krylova
Nadezhda Krylova
MDMaxim Donnikov
Maxim Donnikov
Anton KiselevAnton Kiselev
Anton Kiselev
Spinal muscular atrophy (SMA) is a severe neurodegenerative disorder that has an approved treatment that can still be improved. Antisense oligonucleotides (AONs) are currently delivered intrathecally for SMA therapy based on SMN2 gene splicing correction, and high concentrations are required to achieve an improvement of the disease symptoms. In this study, AONs were introduced into SMA fibroblast cell cultures by means of an arginine–histidine-rich peptide carrier that had been decorated with iRGD ligands. Due to the protected and receptor-mediated nature of AON delivery within these complexes, low concentrations can be used. We assessed the RNA-binding characteristics, cytotoxicity, size, and zeta potential of AON/carrier complexes as well as the efficiency of SMN2 gene splicing correction following transfections. After testing a variety of AON/carrier formulations, we selected those that produced the best outcomes. The AON/carrier complexes that were found to be the most effective significantly increased the proportion of full-length SMN transcripts and the quantity of nuclear gems. Thus, we demonstrated the potential of delivering therapeutic AONs into SMA cells using a ligand-modified peptide carrier.

22 September 2026 in Nanomaterials
Verified
Journal Article
Open access
PDF file
Rodion SakhabeevRodion Sakhabeev
Rodion Sakhabeev
AIArina Ilina
Arina Ilina
IGInga Andreevna Gorbacheva
Inga Andreevna Gorbacheva
ESElizaveta Sezganova
Elizaveta Sezganova
ARAnna Rogova
Anna Rogova
Maxim ShevtsovMaxim Shevtsov
Maxim Shevtsov
The behavior of nanoparticles (NPs) in the body is a complex, multilevel process governed by a cascade of physicochemical and biological interactions. At the molecular level, these processes include protein adsorption and formation of the biomolecular corona, ion release, and surface redox reactions. At the cellular level, they encompass endocytosis, intracellular trafficking, lysosomal processing and clearance, and redistribution within cellular compartments. At the systemic level, NPs undergo tissue and organ biodistribution, biological barrier crossing, biotransformation, biodegradation, elimination, and immunomodulation. Understanding these processes is essential for evaluating the safety, efficacy, and therapeutic potential of nanomedicines, as the unique physicochemical properties of NPs can induce biological responses that differ substantially from those of their bulk counterparts. This review provides an integrated framework for understanding the absorption, distribution, biotransformation, and elimination of NPs in biological systems. Particular emphasis is placed on the molecular and cellular mechanisms governing nanoparticle–biological interactions, including the effects of NPs on cellular energy metabolism through interactions with the mitochondrial electron transport chain and their immunomodulatory effects mediated by nuclear factor κB (NF-κB) signaling and inflammasome activation. By integrating molecular, cellular, and systemic perspectives, this review highlights the key determinants of nanoparticle fate in the body and their implications for the design, safety, and clinical translation of nanomedicines.

28 February 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
Anton KiselevAnton Kiselev
Anton Kiselev
MMMarianna Maretina
Marianna Maretina
SSSofia Shtykalova
Sofia Shtykalova
HHHaya Al Hilal
Haya Al Hilal
NMNatalia Maslyanyuk
Natalia Maslyanyuk
Andrey Sergeevich GlotovAndrey Sergeevich Glotov
Andrey Sergeevich Glotov
Spinal muscular atrophy 5q (SMA) is the most common neuromuscular inherited disease in neonates which is associated with homozygous deletion of exon 7 in the SMN1 gene. Recently established drugs can improve the motor functions of SMA infants when treated in the pre-symptomatic stage. With aim of providing an early diagnosis, newborn screening (NBS) for SMA using real-time PCR assay with dried blood spots (DBS) was performed in Saint-Petersburg from January 2022 through November 2022. Here, 36,140 newborns were screened by GenomeX real-time PCR-based screening test, and three genotypes were determined. Homozygous deletion carriers (4 newborns), heterozygous carriers (772 newborns) and wild-type individuals (35,364 newborns) were identified. All four newborns screened positive for homozygous SMN1 deletion were confirmed by alternate methods. Two of the newborns had two copies of SMN2, and two of the newborns had three copies. We determined Saint-Petersburg spinal muscular atrophy incidence of 1 in 9,035 and SMA carrier frequency of 1 in 47. In conclusion, it can be summarized that providing both timely SMN1 information and confirmation along with SMN2 copy number as part of SMA newborn screening algorithm can significantly improve clinical follow-up, family members testing, and SMA patients' treatment.